英国免疫学会和英国原发性免疫缺陷网络（UKPIN）免疫球蛋白替代治疗管理共识指南。
British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy.
机构信息
Department of Immunology, Royal London Hospital, Barts Health NHS Trust, London, UK.
National Guideline Centre, Royal College of Physicians, London, UK.
出版信息
Clin Exp Immunol. 2022 Oct 21;210(1):1-13. doi: 10.1093/cei/uxac070.
Abstract
Currently, there is no guideline to support the use of immunoglobulin replacement therapy (IgRT) in primary and secondary immunodeficiency disorders in UK. The UK Primary Immunodeficiency Network (UK-PIN) and the British Society of Immunology (BSI) joined forces to address this need. Given the paucity of evidence, a modified Delphi approach was used covering statements for the initiation, monitoring, discontinuation of IgRT as well as home therapy programme. A group of six consultant immunologists and three nurse specialists created the statements, reviewed responses and feedback and agreed on final recommendations. This guideline includes 22 statements for initiation, 22 statements for monitoring, 11 statement for home therapy, and 19 statements for discontinuation of IgRT. Further areas of research are proposed to improve future delivery of care.
摘要
目前，英国尚没有指南支持在原发性和继发性免疫缺陷疾病中使用免疫球蛋白替代疗法（IgRT）。英国原发性免疫缺陷网络（UK-PIN）和英国免疫学会（BSI）联手解决这一需求。鉴于证据不足，采用了改良德尔菲法，涵盖了 IgRT 起始、监测、停止以及家庭治疗方案的陈述。一组六名顾问免疫学家和三名护士专家制定了这些陈述，对回复和反馈进行了审查，并就最终建议达成一致。本指南包括 22 条 IgRT 起始的陈述、22 条 IgRT 监测的陈述、11 条家庭治疗的陈述和 19 条 IgRT 停止的陈述。还提出了进一步的研究领域，以改善未来的护理服务。
相似文献
1
British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy.英国免疫学会和英国原发性免疫缺陷网络（UKPIN）免疫球蛋白替代治疗管理共识指南。
Clin Exp Immunol. 2022 Oct 21;210(1):1-13. doi: 10.1093/cei/uxac070.
2
British Society for Immunology/United Kingdom Primary Immunodeficiency Network consensus statement on managing non-infectious complications of common variable immunodeficiency disorders.英国免疫学会/英国原发性免疫缺陷网络关于常见可变免疫缺陷疾病非传染性并发症管理的共识声明。
Clin Exp Immunol. 2019 Jun;196(3):328-335. doi: 10.1111/cei.13272. Epub 2019 Mar 7.
3
Prescribing Immunoglobulin Replacement Therapy for Patients with Non-classical and Secondary Antibody Deficiency: an Analysis of the Practice of Clinical Immunologists in the UK and Republic of Ireland.为非典型和继发性抗体缺陷患者开具免疫球蛋白替代治疗处方：对英国和爱尔兰共和国临床免疫学家实践的分析。
J Clin Immunol. 2018 Feb;38(2):204-213. doi: 10.1007/s10875-017-0469-4. Epub 2018 Feb 8.
4
Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review.免疫球蛋白替代治疗在自身免疫性风湿病 B 细胞靶向治疗后的继发免疫缺陷：系统文献回顾。
Autoimmun Rev. 2019 May;18(5):535-541. doi: 10.1016/j.autrev.2019.03.010. Epub 2019 Mar 4.
5
Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases.针对自身免疫性风湿病中 B 细胞靶向治疗引起的继发性低丙种球蛋白血症的管理建议。
Rheumatology (Oxford). 2019 May 1;58(5):889-896. doi: 10.1093/rheumatology/key394.
6
Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency.继发性抗体缺乏症患者的免疫球蛋白替代疗法的停用。
Expert Rev Clin Immunol. 2020 Jul;16(7):711-716. doi: 10.1080/1744666X.2020.1788939. Epub 2020 Jul 7.
7
Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.血液恶性肿瘤中继发性免疫缺陷的临床实践现状和挑战。
Eur J Haematol. 2019 Jun;102(6):447-456. doi: 10.1111/ejh.13223. Epub 2019 Mar 24.
8
Immunoglobulin use in immune deficiency in the UK: a report of the UKPID and National Immunoglobulin Databases.英国免疫缺陷患者免疫球蛋白的使用：英国儿科感染性疾病学会和国家免疫球蛋白数据库的报告。
Clin Med (Lond). 2018 Oct;18(5):364-370. doi: 10.7861/clinmedicine.18-5-364.
9
Immunoglobulin replacement for primary immunodeficiency: Indications for initiating and continuing treatment.原发性免疫缺陷的免疫球蛋白替代治疗：开始及持续治疗的指征
Allergy Asthma Proc. 2021 Nov 1;42(6):489-494. doi: 10.2500/aap.2021.42.210082.
10
Risk Factors of Pneumonia in Primary Antibody Deficiency Patients Receiving Immunoglobulin Therapy: Data from the US Immunodeficiency Network (USIDNET).原发性抗体缺陷患者接受免疫球蛋白治疗后发生肺炎的危险因素：来自美国免疫缺陷网络（USIDNET）的数据。
J Clin Immunol. 2022 Oct;42(7):1545-1552. doi: 10.1007/s10875-022-01317-2. Epub 2022 Jul 2.
引用本文的文献
1
[Clinical study on intravenous human immunoglobulin (pH4) for hypogammaglobulinemia and infection risk following CD20 monoclonal antibody therapy in patients with B-cell non-Hodgkin lymphoma].静脉注射人免疫球蛋白（pH4）治疗B细胞非霍奇金淋巴瘤患者CD20单克隆抗体治疗后低丙种球蛋白血症及感染风险的临床研究
Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):425-430. doi: 10.3760/cma.j.cn121090-20240918-00353.
2
Infectious outcomes of a standardized subcutaneous immunoglobulin dose reduction strategy in primary immune deficiencies amid global shortage.在全球短缺的情况下，原发性免疫缺陷患者标准化皮下免疫球蛋白剂量减少策略的感染结局
Front Immunol. 2025 Jan 20;15:1527514. doi: 10.3389/fimmu.2024.1527514. eCollection 2024.
3
Health Care Utilisation in a Cohort of Patients with Primary and Secondary Antibody Deficiency in the United Kingdom.英国原发性和继发性抗体缺陷患者队列的医疗保健利用情况。
J Clin Immunol. 2024 Sep 27;45(1):18. doi: 10.1007/s10875-024-01809-3.
4
Cellular immune response to SARS-CoV-2 in patients with primary antibody deficiencies.原发性抗体缺陷患者对 SARS-CoV-2 的细胞免疫反应。
Front Immunol. 2023 Oct 12;14:1275892. doi: 10.3389/fimmu.2023.1275892. eCollection 2023.
5
Current Approach in the Management of Secondary Immunodeficiency in Patients with Hematological Malignancies: Spanish Expert Consensus Recommendations.血液系统恶性肿瘤患者继发性免疫缺陷管理的当前方法：西班牙专家共识推荐
J Clin Med. 2023 Oct 4;12(19):6356. doi: 10.3390/jcm12196356.
6
Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.体重和年龄对原发性免疫缺陷病患者皮下或透明质酸酶辅助皮下免疫球蛋白 G 药代动力学的影响。
J Clin Immunol. 2023 Nov;43(8):2127-2135. doi: 10.1007/s10875-023-01572-x. Epub 2023 Sep 29.
7
Clinical features and predictors of osteoarticular manifestations in common variable immunodeficiency.常见可变免疫缺陷症的骨关节表现的临床特征和预测因素。
Clin Rheumatol. 2023 Nov;42(11):3123-3129. doi: 10.1007/s10067-023-06722-5. Epub 2023 Jul 28.
8
Clinical and Experimental Immunology: highlights from 2022.《临床与实验免疫学》：2022年亮点
Clin Exp Immunol. 2023 Apr 7;212(1):11-13. doi: 10.1093/cei/uxad018.
本文引用的文献
1
The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management.继发性抗体缺陷的扩展领域：病因、诊断和治疗。
Front Immunol. 2019 Feb 8;10:33. doi: 10.3389/fimmu.2019.00033. eCollection 2019.
2
Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study.不同免疫球蛋白给药方案下 CVID 患者的健康相关生活质量：前瞻性多中心研究。
J Clin Immunol. 2019 Feb;39(2):159-170. doi: 10.1007/s10875-019-0592-5. Epub 2019 Jan 15.
3
Advantage of the subcutaneous immunoglobulin replacement therapy in primary immunodeficient patients with or without secondary protein loss.皮下免疫球蛋白替代疗法在原发性免疫缺陷患者（无论有无继发性蛋白质丢失）中的优势。
Turk J Pediatr. 2018;60(3):270-276. doi: 10.24953/turkjped.2018.03.006.
4
Home-Based Treatment with Immunoglobulins: an Evaluation from the Perspective of Patients and Healthcare Professionals.家庭免疫球蛋白治疗：患者和医疗保健专业人员的评估视角。
J Clin Immunol. 2018 Nov;38(8):876-885. doi: 10.1007/s10875-018-0566-z. Epub 2018 Nov 12.
5
A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions?一组患有原发性免疫缺陷的法国儿科患者：在现实生活条件下，患者对替代免疫疗法的偏好是否得到满足？
Patient Prefer Adherence. 2017 Jul 10;11:1171-1180. doi: 10.2147/PPA.S123363. eCollection 2017.
6
Pneumococcal Antibody Titers: A Comparison of Patients Receiving Intravenous Immunoglobulin Versus Subcutaneous Immunoglobulin.肺炎球菌抗体滴度：接受静脉注射免疫球蛋白与皮下注射免疫球蛋白患者的比较。
Glob Pediatr Health. 2017 Feb 21;4:2333794X16689639. doi: 10.1177/2333794X16689639. eCollection 2017.
7
Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".免疫球蛋白替代疗法的途径是否会影响原发性免疫缺陷患者的生活质量和满意度？来自法国队列研究“Visages”的见解。
Orphanet J Rare Dis. 2016 Jun 22;11(1):83. doi: 10.1186/s13023-016-0452-9.
8
Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia.静脉注射与皮下免疫球蛋白替代治疗继发性低丙种球蛋白血症。
Clin Immunol. 2016 May;166-167:103-4. doi: 10.1016/j.clim.2016.04.001. Epub 2016 Apr 7.
9
Streptococcus pneumoniae antibody titres in patients with primary antibody deficiency receiving intravenous immunoglobulin (IVIG) compared to subcutaneous immunoglobulin (SCIG).与皮下免疫球蛋白（SCIG）相比，接受静脉注射免疫球蛋白（IVIG）的原发性抗体缺陷患者的肺炎链球菌抗体滴度。
Clin Exp Immunol. 2015 Oct;182(1):51-6. doi: 10.1111/cei.12665. Epub 2015 Jul 29.
10
Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study.常规临床实践中对原发性免疫缺陷患者进行皮下免疫球蛋白替代治疗：VISPO前瞻性多中心研究
Clin Drug Investig. 2015 Mar;35(3):179-85. doi: 10.1007/s40261-015-0270-1.
Zotero 插件